{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["6(1)"],"submitter":["Zhu Z"],"pubmed_abstract":["While cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, including palbociclib, combined with endocrine therapy (ET), are becoming the standard-of-care for hormone receptor–positive/human epidermal growth factor receptor 2‒negative metastatic breast cancer, further mechanistic insights are needed to maximize benefit from the treatment regimen. Herein, we conducted a systematic comparative analysis of gene expression/progression-free survival relationship from two phase 3 trials (PALOMA-2 [first-line] and PALOMA-3 [≥second-line]). In the ET-only arm, there was no inter-therapy line correlation. However, adding palbociclib resulted in concordant biomarkers independent of initial ET responsiveness, with shared sensitivity genes enriched in estrogen response and resistance genes over-represented"],"journal":["NPJ precision oncology"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9381541"],"repository":["biostudies-literature"],"pubmed_title":["Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib"],"pmcid":["PMC9381541"],"pubmed_authors":["Gelmon K","Harbeck N","Zhu Z","Cristofanilli M","Cao J","Rejto P","Lu D","VanArsdale T","Andre F","Dieras V","Liu Y","Wei P","Yan Z","Huang X","Turner N","Loibl S","Loi S","Martin M","Finn R","Zhang C","Rugo H"],"additional_accession":[]},"is_claimable":false,"name":"Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib","description":"While cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, including palbociclib, combined with endocrine therapy (ET), are becoming the standard-of-care for hormone receptor–positive/human epidermal growth factor receptor 2‒negative metastatic breast cancer, further mechanistic insights are needed to maximize benefit from the treatment regimen. Herein, we conducted a systematic comparative analysis of gene expression/progression-free survival relationship from two phase 3 trials (PALOMA-2 [first-line] and PALOMA-3 [≥second-line]). In the ET-only arm, there was no inter-therapy line correlation. However, adding palbociclib resulted in concordant biomarkers independent of initial ET responsiveness, with shared sensitivity genes enriched in estrogen response and resistance genes over-represented","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2025-04-04T11:33:30.454Z","creation":"2025-02-19T05:05:59.282Z"},"accession":"S-EPMC9381541","cross_references":{}}